Chimeric Antigen Receptor T-Cell Therapy

Azgar Abdul Rasheed1 Venkata Pradeep Babu Koyyala2

1Department of Medical Oncology, Dr. BRA IRCH, AllMS, New Delhi, India
2Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

Address for correspondence Venkata Pradeep Babu Koyyala, MD, DNB Medical Oncology, Department of Medical, Oncology, Rajiv Gandhi Cancer, Institute and Research Centre, 110085 New Delhi, India (e-mail: pradeepbabu.koyyala@gmail.com).

The beginnings of “Immunotherapy” can arguably be traced back to the ancient Egyptians. They, like James Paget, Wilhelm Busch, and Friedrich Fehleisen in the mid-1800s, observed that some cancer patients experienced tumor regression after suffering from infections. By the late 1800s, the “Father of Immunotherapy” William Coley had started administering injections composed of dead Streptococcus pyogenes and Serratia marcescens as a crude form of immunotherapy. His work was carried forward by his daughter, Helen Coley Nauts, and eventually, Lloyd Old. Old worked on the anti-tumor effects of the Bacillus Calmette-Guérin vaccine and earned the title “Father of Modern Cancer Immunology.”

Today, the domain of immunotherapy has delivered several new armaments in the war against cancer. These include targeted therapies using monoclonal antibodies, cytokine therapy (interferon-α [IFN-α] and interleukin-2 [IL-2]), immune checkpoint inhibitors (anti-CTLA-4, anti-PD1, and anti-PD-L1), oncolytic viruses (T-Vec/talimogene laherparevec), cancer vaccines, immune costimulatory molecules, and adoptive cell therapy (ACT). Founded at the cross-roads of genetic engineering and molecular biology, ACT can be of various types: tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR)-engineered T-cell therapy, natural killer cell therapy, or chimeric antigen receptor (CAR) T-cell therapy. Among these, CAR T-cells have received the most attention and shown the most promise.

In TIL therapy, TILs are extracted from a patient’s tumor biopsy specimen and then cocultured with autologous dendritic cells exposed to neoantigens present in the patient’s tumor. TILs recognizing the patient-specific neoantigens are then selected, expanded in vitro using IL-2, and then infused back into the patient. TIL therapy has shown some promise in melanomas, colorectal cancer, and breast cancer. TCR T-cell therapy is less invasive than TIL therapy as the required lymphocytes are sourced from the patient’s peripheral blood and are more proliferative than TILs. After extraction, purification, and activation, the T-cells are genetically modified by retroviral/lentiviral transduction or nonviral methods (such as electroporation or transposon delivery systems) to express cell-surface receptors targeting specific antigens. These are still natural receptors and can detect antigens from anywhere in the cell, as long as they are presented to them by the major histocompatibility complex (MHC) molecules. Trials have shown some benefit in sarcomas and melanomas. However, they can only target peptide antigens and, to be effective, require adequate MHC expression by the patient’s tumor cells. TCRs may also cross-react with endogenous antigens and, hence, carry a risk of induced severe autoimmunity. The more advanced CAR T-cells have the advantage that they are not MHC restricted and can recognize both protein and nonprotein antigens independently of the MHC, without antigen processing/presentation by the target cells. Thus, they can be engineered against a wider array of targets. The “chimeric” in CARs refers to the fact that these combine both antigen-binding and T-cell activation functions into a single synthetic receptor. The antigen binding in CAR T-cells is achieved through the use of specific recombinant antibodies in the extracellular domain, earning them the nickname “T-bodies.” Just like TILs, TCR and CAR T-cells are also clonally expanded in vitro and, then, after subjecting the patient to a lymphodepleting chemotherapy, infused back into the patient, often with in vivo IL-2 support. The steps involved in CAR T-cell therapy are shown in Fig. 1.

“Immunotherapy” was the ASCO “Advance of the Year” in 2016 and 2017, and in 2018, the honor went to CAR T-cell research. Yet, the work had started much earlier, with Zelig Eshhar proposing the concept in the early 1980s and, subsequently, engineering the first CAR T-cell. First-generation CAR T-cells coupled an extracellular single-chain variable fragment (scFv) with an intracellular CD3-ξ (zeta) signaling domain. A scFv should not be thought of as an antibody fragment; it is a fusion protein made by joining variable regions of light (\(V_L\)) and heavy (\(V_H\)) immunoglobulin chains with a peptide linker. Michel Sadelain was the first to conduct
clinical trials in this area and used second-generation CAR T-cells with additional co-signaling molecules such as 4–1BB or CD28. He called these cells “living drugs,” capable of greater in vivo clonal expansion and longer persistence in circulation. In 2017, two CAR T-cell therapies received the Food and Drug Administration (FDA) approval—tisagenlecleucel and axicabtagene ciloleucel, both of which target CD19 (►Table 1). The evolution of CAR T-cell therapy is depicted in ►Fig. 2.

### Second-Generation Chimeric Antigen Receptor T-Cells

Tisagenlecleucel (Kymriah, Novartis, Basel, Switzerland) has an anti-CD19 extracellular domain coupled with CD3-ξ and 4–1BB intracellular signaling domains. The 4–1BB domain is thought to increase the persistence of CAR T-cells by countering T-cell exhaustion. It is approved in patients aged <25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory to standard treatment or in second or later relapse1 and adults with R/R large B-cell lymphoma post >2 lines of systemic therapy.2 Due to the risk of cytokine release syndrome (CRS) and neurotoxicities, the FDA approval was conditional on the basis of approved Risk Evaluation and Mitigation Strategies, which includes having a minimum of two doses of tocilizumab available for each patient for immediate administration.

Axicabtagene ciloleucel (Yescarta, Kite Pharma, Los Angeles, California, USA Inc.) is an anti-CD19, with a CD28 co-stimulatory domain. Axi-cel has received the FDA approval for treating adults with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL)-not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.3

Next on the horizon for the FDA approval is the CD19-targeted, 4–1BB CAR T-cell product lisocabtagene...

---

### Table 1  Food and Drug Administration-approved chimeric antigen receptor T-cell therapies

<table>
<thead>
<tr>
<th>Name</th>
<th>Tisagenlecleucel (Kymriah, Novartis)</th>
<th>Axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR</td>
<td>Anti-CD19 with 4–1BB costimulatory domain</td>
<td>Anti-CD19 with CD28 costimulatory domain</td>
</tr>
<tr>
<td>Indications</td>
<td>Patients aged ≤25 years with B-cell</td>
<td>R/R large B-cell lymphoma post</td>
</tr>
<tr>
<td></td>
<td>Precursor ALL refractory to standard treatment or in second or later relapse</td>
<td>≥2 lines of systemic therapy</td>
</tr>
<tr>
<td>Approval based on</td>
<td>Phase II JULIANA trial in 75 children and young adults with CD19+ relapsed or refractory B-cell ALL</td>
<td>Single-arm Phase II JULIET trial</td>
</tr>
<tr>
<td>Outcome</td>
<td>The overall remission rate at 3 months was 81%, and all those who responded had no detectable MRD as determined by flow cytometry. At 12 months, the EFS was 50% (95% CI: 35, 64) and OS was 76% (95% CI: 63, 86). The median duration of remission was not reached. Tisa-cel was found to persist in the blood even at 20 months after administration.</td>
<td>Overall response rate of 52% (95% CI: 41–62); 40% had CR and 12% had PR. At 12 months after the initial response, estimated RFS was 65%. At 12 months, RFS was 79% among patients who had achieved a CR</td>
</tr>
<tr>
<td>Toxicities</td>
<td>73% of patients had Grade 4 adverse events. 77% of patients experienced CRS and 20% had neurological toxicities.</td>
<td>The most common Grade 4 adverse events were CRS (22%), neurologic toxicities (12%), cytopenias (32%), infections (20%), and febrile neutropenia (14%).</td>
</tr>
</tbody>
</table>

Abbreviations: CRS, cytokine release syndrome; CAR, chimeric antigen receptor; OS, overall survival; CI, confidence interval; MRD, measurable residual disease; EFS, event-free survival; ORR, objective response rate; CR, complete response; PMBCL, primary mediastinal large B-cell lymphoma; FL, follicular lymphoma; DLBCL-NOS, diffuse large B-cell lymphoma-not otherwise specified; ALL, acute lymphoblastic leukemia; RFS, relapse-free survival; PR, partial response.
being tested in multiple myeloma. Antigen loss. B-cell maturation agent-targeted CAR T-cells are tandem CAR (TanCAR) designs have been found to prevent targets, such as CD19 and CD23 simultaneously, and these anti-CD22 CAR T-cell therapies. Some studies have used dual expressing the CD19 antigen. This may then respond to anti-CD19-based therapy, around a third will eventually relapse. This is often due to a phenomenon called “antigen loss” where the malignant cells simply stop potentially responding to therapy. Of the relapsed B-cell ALL patients who initially respond to anti-CD19-based therapy, around a third will eventually relapse. This is often due to a phenomenon called “antigen loss” where the malignant cells simply stop expressing the CD19 antigen. This may then respond to anti-CD22 CAR T-cell therapies. Some studies have used dual targets, such as CD19 and CD23 simultaneously, and these tandem CAR (TanCAR) designs have been found to prevent antigen loss. B-cell maturation agent-targeted CAR T-cells are being tested in multiple myeloma.

Third- and Fourth-Generation Chimeric Antigen Receptor T-Cells

Third-generation CAR T-cells have two tandem costimulatory domains, for example, both CD28 and 4–1BB, along with CD3-ζ. CAR T-cells have not been successful in solid tumors because they do not express cell-surface antigens to the extent found in hematological malignancies. Trials targeting mesothelin in lung/pancreatic cancers and epidermal growth factor receptor in glioblastomas have failed. The immunosuppressive tumor microenvironments inherent in solid cancers have also been found to be troublesome. To address this issue, fourth-generation CAR T-cells known as T-cells redirected for expression normal cells that express the target antigen. For example, this has not been proven to occur. Then, there are on-target, off-tumor toxicities that occur due to the CAR T-cells attacking normal cells that express the target antigen. For example, this can manifest as B-cell aplasia and hypogammaglobulinemia, due to the CAR T-cells attacking normal B-cells carrying the CD19 antigen. This is partially compensated for by immunoglobulin transfusions. Other common side effects include tumor lysis syndrome, anaphylaxis, and neurological toxicities such as immune effector cell-associated neurotoxicity syndrome.

What Lies Ahead

Off-the-shelf CAR T-cell therapies are also being tested. These are manufactured from healthy donors, not individual patients, and hence provide savings on cost and time. Cellectis has been manufacturing these using transcription activator-like effector nucleases for gene editing. In the future, nanotechnology may even enable the engineering of CAR T-cells within the body. Clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing technology may permit greater precision in T-cell engineering. Sadelain et al utilized this technology to insert a CAR cassette specifically in the T-cell receptor α-chain gene. These CRISPR-edited CAR T-cells are more effective than conventional CAR T-cells at killing malignant cells. They also suffer less “exhaustion,” that is, they are less likely to stop recognizing and killing tumor cells with the passage of time. The CRISPR-Cas9 technique is also safer than the retroviral/lentiviral-mediated random insertion used in conventional CAR T-cells because it decreases the risk of creating harmful mutations. CAR T-cells may even come with inbuilt “off-switches” to protect against CRS. In February 2020, the FDA approved an investigational new drug application for such a “switchable” CAR T cell therapy being evaluated for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Toxicities

The most significant toxicity of CAR T-cell therapy is CRS. It is characterized by a sudden flood of pro-inflammatory cytokines (IFN-γ, tumor necrosis factor-α, IL-6, IL-10, etc.) leading to exaggerated and uncontrolled immune activation. This, in turn, causes fever, capillary leakage, hypotension, tachycardia, respiratory failure, and eventually, multiorgan dysfunction. CRS is an on-target, on-tumor toxicity, indicating that the infused T-cells are functioning as expected. In fact, the greater the disease burden and the T-cell dose infused, the higher the risk of CRS. Besides supportive care, the IL-6 receptor antagonist tocilizumab (Actemra) has become the standard drug for the treatment of CRS. The American Society for Transplantation and Cellular Therapy Consensus grading of CRS and the appropriate treatment for each grade are shown in Table 2. Steroids are usually reserved for severe CRS due to concerns that steroid therapy may deplete the infused CAR T-cells, although this has not been proven to occur. Then, there are on-target, off-tumor toxicities that occur due to the CAR T-cells attacking normal cells that express the target antigen. For example, this can manifest as B-cell aplasia and hypogammaglobulinemia, due to the CAR T-cells attacking normal B-cells carrying the CD19 antigen. This is partially compensated for by immunoglobulin transfusions. Other common side effects include tumor lysis syndrome, anaphylaxis, and neurological toxicities such as immune effector cell-associated neurotoxicity syndrome.
Currently available CAR T-cell therapies cost hundreds of thousands of dollars in the United States. In India, many groups, including one from IIT Bombay, have been at work trying to deliver the technology here at a fraction of the price. Work is also ongoing for developing an indigenous CAR T-cell platform. Patients in India may possibly have access to T-cell therapy here by the end of this year.

**Financial Support and Sponsorship**
Nil.

**Conflicts of Interest**
There are no conflicts of interest.

**References**

**Table 2**  Grading and treatment of cytokine release syndrome

<table>
<thead>
<tr>
<th>Grade</th>
<th>Criteria</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Fever ≥38°C not attributable to any other cause</td>
<td>For mild CRS, Symptomatic Treatment plus Product-specific Risk Evaluation and Mitigation Strategies (REMS)</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Fever ≥38°C plus hypotension not requiring vasopressors OR hypoxia requiring low-flow oxygen (≤6 L/min)</td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td>Fever ≥38°C plus hypotension requiring one vasopressor OR hypoxia requiring high-flow oxygen by nasal cannula/ face-mask/ Venturi mask</td>
<td>For severe CRS, Tocilizumab (&lt;30kg – 12mg/kg, ≥30kg – 8mg/kg) IV over 1 hour q8h x maximum 4 doses plus Steroid Therapy (Inj. Hydrocortisone 100mg IV q8h, or methylprednisolone 1mg/kg/day, etc.)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Fever ≥38°C plus hypotension requiring &gt;1 vasopressors OR hypoxia requiring positive-pressure ventilation</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CRS, cytokine release syndrome; CAR, chimeric antigen receptor; OS, overall survival; CI, confidence interval; MRD, measurable residual disease; EFS, event-free survival; ORR, objective response rate; CR, complete response; PMBCL, primary mediastinal large B-cell lymphoma, FL, follicular lymphoma; DLBCL-NOS, diffuse large B-cell lymphoma-not otherwise specified; ALL, acute lymphoblastic leukemia; RFS, relapse-free survival; PR, partial response.